Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000-2007.

We report a retrospective study of 24 patients with haematological malignancy and hepatosplenic candidiasis. Clinical and biological features were similar to previous reports. No patient previously received antifungal prophylaxis. Liver or spleen histological examination revealed yeasts in 6/24 patients (25%) on direct examination but all cultures were negative. After a median duration of 7 months, antifungal treatment was discontinued in 58% of the patients with no relapse. Eleven (46%) patients died during follow up. After multivariate analysis, independent factors associated with death were the duration of neutropenia (p 0.022) and relapsing haematological malignancy (p 0.015).

[1]  C. Maunoury,et al.  Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  H. Gundacker,et al.  Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  V. Anttila,et al.  Effect of fluconazole prophylaxis on the incidence of invasive candida infections and bacteraemias in patients with acute leukaemia , 2008, European journal of haematology.

[6]  P. Rohrlich,et al.  Adjuvant corticosteroid therapy for chronic disseminated candidiasis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Z. Khan,et al.  Comparative evaluation of (1, 3)-β-D-glucan, mannan and anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia , 2007, BMC infectious diseases.

[8]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[9]  S. Sallah,et al.  Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. , 2005, Leukemia research.

[10]  M. Yao,et al.  Hepatosplenic fungal infection in patients with acute leukemia in Taiwan: incidence, treatment, and prognosis , 2003, Annals of Hematology.

[11]  D. Kontoyiannis,et al.  Pulmonary candidiasis in patients with cancer: an autopsy study. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  K. Yuen,et al.  Immunorestitution Diseases in Patients not Infected with HIV , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[13]  D. Kontoyiannis,et al.  Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. , 2000, Infectious disease clinics of North America.

[14]  A. Ganser,et al.  Hepatosplenic candidiasis in patients with acute leukaemia , 2000, British journal of haematology.

[15]  V. Anttila,et al.  Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Hackman,et al.  Fungal liver infection in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  E. Anaissie,et al.  Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. , 1991, The American journal of medicine.

[18]  D. R. Weber,et al.  Hepatosplenic candidiasis: successful treatment with fluconazole. , 1991, The American journal of medicine.

[19]  L. Mele,et al.  Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. , 2002, Haematologica.